Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Efficacy of Chemokine Receptor Inhibition in Treating IL-36α-Induced Psoriasiform Inflammation.

Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Wang Y, Yau S, Mali VR, Chhina V, Kumamoto A, Liu S, Dang T, Newland D, Charo IF, Zhang P, Schall TJ, Singh R.

J Immunol. 2019 Mar 15;202(6):1687-1692. doi: 10.4049/jimmunol.1801519. Epub 2019 Feb 4.

PMID:
30718298
2.

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ.

PLoS One. 2019 Jan 4;14(1):e0210593. doi: 10.1371/journal.pone.0210593. eCollection 2019.

3.

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS).

Miao Z, Ertl LS, Newland D, Zhao B, Wang Y, Zang X, Campbell JJ, Liu X, Dang T, Miao S, Krasinski A, Punna S, Zeng Y, McMahon J, Zhang P, Charo IF, Schall TJ, Singh R.

PLoS One. 2018 Mar 21;13(3):e0192405. doi: 10.1371/journal.pone.0192405. eCollection 2018.

4.

CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.

Parker R, Weston CJ, Miao Z, Corbett C, Armstrong MJ, Ertl L, Ebsworth K, Walters MJ, Baumart T, Newland D, McMahon J, Zhang P, Singh R, Campbell J, Newsome PN, Charo I, Schall TJ, Adams DH.

Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G483-G493. doi: 10.1152/ajpgi.00213.2017. Epub 2018 Feb 8.

5.

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC.

Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30.

6.

IL-17-Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin.

Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Newland D, Wang Y, Liu S, Miao Z, Dang T, Zhang P, Charo IF, Singh R, Schall TJ.

J Immunol. 2017 Nov 1;199(9):3129-3136. doi: 10.4049/jimmunol.1700826. Epub 2017 Sep 29.

7.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

8.

Structural basis of ligand interaction with atypical chemokine receptor 3.

Gustavsson M, Wang L, van Gils N, Stephens BS, Zhang P, Schall TJ, Yang S, Abagyan R, Chance MR, Kufareva I, Handel TM.

Nat Commun. 2017 Jan 18;8:14135. doi: 10.1038/ncomms14135.

9.

Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells.

Demir IE, Kujundzic K, Pfitzinger PL, Saricaoglu ÖC, Teller S, Kehl T, Reyes CM, Ertl LS, Miao Z, Schall TJ, Tieftrunk E, Haller B, Diakopoulos KN, Kurkowski MU, Lesina M, Krüger A, Algül H, Friess H, Ceyhan GO.

Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E85-E94. doi: 10.1073/pnas.1606909114. Epub 2016 Dec 16.

10.

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ.

PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016. Erratum in: PLoS One. 2019 Jan 4;14(1):e0210593.

11.

Tissue proteases convert CCL23 into potent monocyte chemoattractants in patients with chronic rhinosinusitis.

Poposki JA, Keswani A, Kim JK, Klingler AI, Suh LA, Norton J, Carter RG, Peters AT, Hulse KE, Grammer LC, Tan BK, Conley DB, Jaen JC, Schall TJ, Kern RC, Kato A.

J Allergy Clin Immunol. 2016 Apr;137(4):1274-1277.e9. doi: 10.1016/j.jaci.2015.09.029. Epub 2015 Nov 10. No abstract available.

12.

CCR9 Antagonists in the Treatment of Ulcerative Colitis.

Bekker P, Ebsworth K, Walters MJ, Berahovich RD, Ertl LS, Charvat TT, Punna S, Powers JP, Campbell JJ, Sullivan TJ, Jaen JC, Schall TJ.

Mediators Inflamm. 2015;2015:628340. doi: 10.1155/2015/628340. Epub 2015 Sep 20.

13.

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9.

PMID:
26268910
14.

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice.

Yokoyama W, Kohsaka H, Kaneko K, Walters M, Takayasu A, Fukuda S, Miyabe C, Miyabe Y, Love PE, Nakamoto N, Kanai T, Watanabe-Imai K, Charvat TT, Penfold ME, Jaen J, Schall TJ, Harigai M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2014 Sep 24;16(5):445. doi: 10.1186/s13075-014-0445-9.

15.

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM.

Br J Cancer. 2014 Mar 4;110(5):1179-88. doi: 10.1038/bjc.2013.830. Epub 2014 Jan 14.

16.

Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue.

Li X, Zhu M, Penfold ME, Koenen RR, Thiemann A, Heyll K, Akhtar S, Koyadan S, Wu Z, Gremse F, Kiessling F, van Zandvoort M, Schall TJ, Weber C, Schober A.

Circulation. 2014 Mar 18;129(11):1244-53. doi: 10.1161/CIRCULATIONAHA.113.006840. Epub 2013 Dec 27.

PMID:
24374972
17.

C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC.

J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31.

18.

Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.

Berahovich RD, Zabel BA, Lewén S, Walters MJ, Ebsworth K, Wang Y, Jaen JC, Schall TJ.

Immunology. 2014 Jan;141(1):111-22. doi: 10.1111/imm.12176.

19.

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, Zhao BN, Baumgart T, Ertl LS, Pennell A, Seitz L, Powers J, Zhao R, Ungashe S, Wei Z, Boring L, Tsou CL, Charo I, Berahovich RD, Schall TJ, Jaen JC.

Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1288-97. doi: 10.1152/ajprenal.00316.2013. Epub 2013 Aug 28.

20.

Differences in CXCR7 protein expression on rat versus mouse and human splenic marginal zone B cells.

Berahovich RD, Penfold ME, Miao Z, Walters MJ, Jaen JC, Schall TJ.

Immunol Lett. 2013 Jul-Aug;154(1-2):77-9. doi: 10.1016/j.imlet.2013.08.004. Epub 2013 Aug 14. No abstract available.

PMID:
23954811
21.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC.

Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15.

PMID:
23953944
22.

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.

Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group.

PLoS One. 2013;8(3):e60094. doi: 10.1371/journal.pone.0060094. Epub 2013 Mar 20.

23.

CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens.

Walters MJ, Ebsworth K, Sullivan TJ, Zhang P, Powers JP, Jaen JC, Schall TJ.

Immunol Lett. 2013 Mar;151(1-2):44-7. doi: 10.1016/j.imlet.2013.01.006. Epub 2013 Jan 16.

24.

A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking.

Tubo NJ, Wurbel MA, Charvat TT, Schall TJ, Walters MJ, Campbell JJ.

PLoS One. 2012;7(11):e50498. doi: 10.1371/journal.pone.0050498. Epub 2012 Nov 29.

25.

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC.

Blood. 2012 Aug 16;120(7):1449-57. doi: 10.1182/blood-2011-10-384784. Epub 2012 May 22.

26.

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial.

Tak PP, Balanescu A, Tseluyko V, Bojin S, Drescher E, Dairaghi D, Miao S, Marchesin V, Jaen J, Schall TJ, Bekker P.

Ann Rheum Dis. 2013 Mar;72(3):337-44. doi: 10.1136/annrheumdis-2011-201605. Epub 2012 May 15.

PMID:
22589376
27.

Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.

Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou CL, Charo IF, Bekker P, Schall TJ, Jaen JC.

J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. Epub 2012 Jun 5. Retraction in: J Pharmacol Exp Ther. 2012 Jul;342(1):234.

PMID:
22378937
28.

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells.

Zabel BA, Lewén S, Berahovich RD, Jaén JC, Schall TJ.

Mol Cancer. 2011 Jun 14;10:73. doi: 10.1186/1476-4598-10-73.

29.

Overcoming hurdles in developing successful drugs targeting chemokine receptors.

Schall TJ, Proudfoot AE.

Nat Rev Immunol. 2011 May;11(5):355-63. doi: 10.1038/nri2972. Epub 2011 Apr 15. Review.

PMID:
21494268
30.

Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC.

Clin Pharmacol Ther. 2011 May;89(5):726-34. doi: 10.1038/clpt.2011.33. Epub 2011 Mar 30.

PMID:
21451509
31.

CXCR7 protein is not expressed on human or mouse leukocytes.

Berahovich RD, Zabel BA, Penfold ME, Lewén S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, McGrath KE, Jaen JC, Schall TJ.

J Immunol. 2010 Nov 1;185(9):5130-9. doi: 10.4049/jimmunol.1001660. Epub 2010 Oct 1.

32.

CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells.

Zabel BA, Miao Z, Lai NL, Wang Y, Lewén S, Berahovich RD, Jaén JC, Schall TJ.

Oncol Lett. 2010 Sep;1(5):845-847. Epub 2010 Sep 1.

33.

Nonspecific CXCR7 antibodies.

Berahovich RD, Penfold ME, Schall TJ.

Immunol Lett. 2010 Oct 30;133(2):112-4. doi: 10.1016/j.imlet.2010.06.010. Epub 2010 Aug 6. No abstract available.

PMID:
20691730
34.

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ.

J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. doi: 10.1124/jpet.110.169714. Epub 2010 Jul 21.

PMID:
20660125
35.

Pathogenic role of CXCR7 in rheumatoid arthritis.

Watanabe K, Penfold ME, Matsuda A, Ohyanagi N, Kaneko K, Miyabe Y, Matsumoto K, Schall TJ, Miyasaka N, Nanki T.

Arthritis Rheum. 2010 Nov;62(11):3211-20. doi: 10.1002/art.27650.

36.

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.

Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ, Mentlein R.

Cancer Res. 2010 Apr 15;70(8):3299-308. doi: 10.1158/0008-5472.CAN-09-3642. Epub 2010 Apr 13.

37.

Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.

Zabel BA, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC, Schall TJ.

J Immunol. 2009 Sep 1;183(5):3204-11. doi: 10.4049/jimmunol.0900269. Epub 2009 Jul 29.

38.

A human T cell-specific molecule is a member of a new gene family. 1988.

Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM.

J Immunol. 2009 Apr 1;182(7):3947-54. No abstract available.

39.

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ.

Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40. Epub 2007 Sep 26.

40.

Proinflammatory proteases liberate a discrete high-affinity functional FPRL1 (CCR12) ligand from CCL23.

Miao Z, Premack BA, Wei Z, Wang Y, Gerard C, Showell H, Howard M, Schall TJ, Berahovich R.

J Immunol. 2007 Jun 1;178(11):7395-404.

41.

Fractalkine expression in the rhesus monkey brain during lentivirus infection and its control by 6-chloro-2',3'-dideoxyguanosine.

Depboylu C, Eiden LE, Schäfer MK, Reinhart TA, Mitsuya H, Schall TJ, Weihe E.

J Neuropathol Exp Neurol. 2006 Dec;65(12):1170-80.

PMID:
17146291
42.

Evidence for NK cell subsets based on chemokine receptor expression.

Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ.

J Immunol. 2006 Dec 1;177(11):7833-40.

43.

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ.

J Exp Med. 2006 Sep 4;203(9):2201-13. Epub 2006 Aug 28.

44.

Optimization of 2-aminothiazole derivatives as CCR4 antagonists.

Wang X, Xu F, Xu Q, Mahmud H, Houze J, Zhu L, Akerman M, Tonn G, Tang L, McMaster BE, Dairaghi DJ, Schall TJ, Collins TL, Medina JC.

Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. Epub 2006 Feb 23.

PMID:
16497499
45.

Proteolytic activation of alternative CCR1 ligands in inflammation.

Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ.

J Immunol. 2005 Jun 1;174(11):7341-51.

46.

Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function in vivo.

Sparer TE, Gosling J, Schall TJ, Mocarski ES.

J Interferon Cytokine Res. 2004 Oct;24(10):611-20.

PMID:
15626158
47.

Characterization of the rhesus cytomegalovirus US28 locus.

Penfold ME, Schmidt TL, Dairaghi DJ, Barry PA, Schall TJ.

J Virol. 2003 Oct;77(19):10404-13.

48.

Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10.

Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, Schall TJ.

J Virol. 2002 Feb;76(3):1285-92. Erratum in: J Virol 2002 Apr;76(7):3585.

49.

Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics.

Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ.

J Biol Chem. 2002 Jan 25;277(4):2785-9. Epub 2001 Nov 5.

50.

Chemokines and myeloid cell recruitment.

Greaves DR, Schall TJ.

Microbes Infect. 2000 Mar;2(3):331-6. Review.

PMID:
10758411

Supplemental Content

Loading ...
Support Center